The CBF has already undertaken Process Development work and will shortly be manufacturing the first adenovirus vaccine candidate for Crohn's disease. The vaccine is co-developed by Prof John Hermon-Taylor of HAV Vaccines Ltd. and Prof Sarah Gilbert of the Jenner institute. The vaccine is designed to contain antigens to Mycobacterium avium subspecies paratuberculosis (MAP), which is the causative agent for Johne's disease in cattle and has been linked to Crohn's disease in humans. A similar vaccine expressing the same antigens (HAV polypeptide) was tested recently in cattle with very encouraging results. The novel Crohn's disease adenovirus vaccine will be tested in a Phase I trial next year with a Phase IIa trial to follow.